Creative Destruction Lab

Arkangel AI is a company focused on improving global health outcomes by utilizing an artificial intelligence platform designed to detect preventable diseases quickly and accurately. By achieving a detection accuracy of 90%, the platform generates results in seconds, making it a scalable and cost-effective solution for identifying diseases, especially in remote areas with limited healthcare infrastructure. Founded in 2019, Arkangel AI aims to reduce the death rate from viral diseases by combining scientific advancements with community knowledge, ensuring that equal health conditions are accessible to everyone worldwide. The company operates offices in Canada and Colombia.

Nanology Labs Inc., founded in 2018 and based in Toronto, Canada, focuses on developing a nano-theranostic platform technology aimed at detecting and treating cancers. The company's flagship product, Manganescan, serves as a novel theranostic agent that functions both as an MRI contrast agent and a radio-sensitizer. Manganescan enhances the detection of brain tumors at early stages by producing Mn2+ ions, which oxygenate the tumor environment and improve the efficacy of radiation therapy. This innovative agent is three times more sensitive than existing Gadolinium-based contrast agents and is capable of crossing the blood-brain barrier, allowing for early and precise identification and targeting of brain cancer.

Developer of an immune monitoring platform designed to assist in blood analytics and remote health monitoring. The company's technology utilizes artificial intelligence to perform remote blood testing and assess the risk from home for a particular condition, enabling doctors to monitor their patient's health in an enhanced manner.

Developer of home-monitoring applications designed to measure eyesight. The company's software combines vision science and computer science to measure sight as precisely and reliably as physically possible, enabling patients who are at high risk of eye disease to self-monitor from home and avoid the hospital. .

Kraken Sense develops an automated pathogen detection platform that includes sensors to detect bacterial contamination in real-time, using cutting edge nanotechnology and state of the art calibration techniques. The company's solution makes monitoring low-cost and easy to use with an IoT enabled dashboard and analytics tools.

Unravel Biosciences develops a vertically integrated computational platform to improve drug discovery. Unravel’s platform screens many drugs in parallel for their real-world impact (e.g., the complete gene expression profiles and resulting physiological changes), reversing this process to identify the likely target(s) a drug is interacting with.

BioHuntress Therapeutics is a nature-inspired, scientifically validated, patent-protected drug development platform. BioHuntress was founded and incorporated in August 2016 and works in collaboration with advanced laboratories in Atlantic Canada. BioHuntress was born out of the desire to see valuable research being applied outside of academia. Its current long-term vision is to establish itself as a life science incubator that strives to bring academia-born inventions out of the lab and to the public.

Heart I/O is a digital diagnostic startup using artificial intelligence to help emergency providers identify heart abnormalities more quickly, more accurately, and for orders of magnitude less. It was started in 2018 and is headquartered in Pittsburgh, Pennsylvania.

Circadian Positioning Systems specializes in circadian-targeted technology aimed at enhancing performance in critical work environments. The company develops innovative solutions that incorporate wearable sensors and circadian-based light interventions. These technologies are designed to adjust an individual's circadian rhythm, promoting optimal physical and mental performance during work hours and improving sleep quality during designated rest periods. By addressing the effects of tiredness and fatigue, Circadian Positioning Systems enables users to maintain high levels of productivity and well-being in demanding situations.

Modality.AI, Inc. specializes in AI-driven healthcare screening solutions that focus on monitoring and assessing patients' health through conversational interactions. The company's platform utilizes audio-visual biomarkers and engages patients via dialogue and video to provide continuous health assessments. This technology is particularly beneficial for pharmaceutical companies, as it enhances the efficiency of clinical trials for therapies targeting neurological and mental health conditions. By analyzing multimodal data, Modality.AI delivers objective measures that correlate with clinical outcomes, facilitating self-driven neurological assessments. Founded in 2018 and headquartered in San Francisco, California, Modality.AI aims to improve health evaluations and streamline the clinical trial process.

Diadem Biotherapeutics is a biotechnology company that focuses on creating bio-therapeutical materials produced using organic means. Diadem develops exosomes to treat chronic inflammatory and auto-immune conditions.

Neurolytic Healthcare Ltd. is a company based in Oxford, United Kingdom, specializing in the design, development, manufacturing, and delivery of digital and genomic-based diagnostic tools and medical devices aimed at treating migraine and related neurological disorders. Established in 2016, the company focuses on personalized medicine by integrating genetic and biomarker data to enhance diagnostic accuracy and assist clinicians in determining optimal treatment strategies. Its product offerings include a diagnostic support tool, a pharmacogenetic test, and a mobile application designed for predicting migraine events. Through these innovative solutions, Neurolytic Healthcare aims to improve the management and treatment of neurological conditions.

DeepLife uses deep learning on multi-omics data to model cells and efficiently engineer their behavior. DeepLife is a biotech company with a mission to build the next generation of system biology. The company works in a highly collaborative translational manner, to facilitate the transition of discoveries from the laboratory to patients. The company operates through collaboration with academic groups in their respective areas of expertise.

Ariel Precision Medicine is an integrated genomics and digital health company based in Pittsburgh, Pennsylvania, that focuses on providing precision medicine solutions for the diagnosis, monitoring, and treatment of complex chronic diseases. Founded in 2013, the company develops innovative clinical decision support tools designed to simplify personalized treatment, particularly through its flagship product, ArielDx. This cloud-based platform specifically aids in the diagnosis and management of pancreatic disease, enhancing the capabilities of healthcare providers in both emergency and clinical settings. Ariel Precision Medicine aims to improve patient outcomes by leveraging advanced technology and genomic insights in healthcare.

DeepSpin GmbH, founded in 2019 and headquartered in Berlin, Germany, specializes in the development of an innovative artificial intelligence (AI)-based magnetic resonance imaging (MRI) system. This next-generation imaging machine is designed to be significantly smaller, lighter, and more affordable than conventional MRI systems. By utilizing generative topological design for its hardware and deep learning algorithms for image processing, DeepSpin aims to enhance the accessibility of medical imaging, making it available to patients worldwide. The company's technology seeks to modernize medical imaging, providing a standard of care that can reach previously underserved medical domains.

Alpenglow Biosciences, based in Seattle, Washington, specializes in advanced imaging technology for biological research. The company manufactures flatbed scanners designed for tissue analysis, which generate rich 3D molecular datasets. Its flagship product is an open-top light-sheet microscopy system that allows for the 3D scanning of intact biological samples, enhancing the capabilities of pathologists and researchers. Founded in 2018, Alpenglow aims to modernize pathology and improve the understanding of complex biological processes through its innovative imaging solutions.

Albus Health is a medical device company that develops a passive and non-contact, nocturnal symptom monitoring device. The company develops Albus Home RD, a completely passive and non-contact home monitoring device that enables a high quantity and quality of data from remote monitoring in research and clinical care.

Hyivy Health specializes in developing an innovative pelvic rehabilitation device aimed at addressing the needs of women experiencing pelvic health complications, which affect one in three women globally. The company's device stands out by offering the first quantifiable data set on pelvic floor health, utilizing multiple biosensors and mechanical functions to deliver three distinct therapeutic approaches. This technology enables patients and their healthcare providers to monitor progress, adapt treatment plans, and enhance the overall rehabilitation experience. By integrating remote therapeutic and monitoring capabilities, Hyivy Health aims to improve the management of pelvic and gynecological conditions, providing a more effective and comfortable solution for patients.

Developer of nanotechnology-based medical products intended to provide biocompatible and bio-selective wound dressings. The company commercializes nanotechnology in the health and decontamination sectors beginning with chronic wounds like diabetic foot ulcers, providing clinicians with small and mighty components to address unmet health needs.

GuideStar Medical Devices is a med-tech start-up that transforms medical procedures, improves safety, and reduces cost.

SynchroPET Inc. specializes in the development of innovative Positron Emission Tomography (PET) imaging systems for both medical research and clinical applications. Founded in 2013 and based in Stony Brook, New York, the company offers a range of products including PET/MRI systems for comprehensive preclinical research, a portable Mini-PET device for laboratory mobility, and the RatCAP, which allows for unobstructed animal movement during imaging. Additionally, the Wrist PET Detector is designed for non-invasive clinical use. SynchroPET's technologies aim to enhance diagnostic accuracy and treatment efficacy for diseases such as cancer, Alzheimer's, and Parkinson's by providing improved resolution and quantitative data, thus facilitating personalized medical treatments and accelerating research potential.

Applikate Technologies is a hardware and software company that develops a fully automated histology platform with integrated digital imaging. The platform automates the pathology workflow, reducing processing time, lowering cost, and improving image quality, which reduces the risk of misdiagnosis.

Clinia is a health search engine designed to enhance operational workflows and improve patient navigation for healthcare organizations. Its modular, AI-powered infrastructure allows clients to create customized search experiences on their websites, portals, or applications, facilitating easier access to trusted healthcare resources. By understanding individual circumstances, Clinia’s technology aids in the classification and discovery of health information, enabling organizations to implement personalized navigation solutions. This capability empowers care teams to deliver efficient and timely care while supporting patients in managing their health more effectively.

Index Biosystems is a provider of genetic traceability solutions focused on ensuring source-of-origin identification in food systems. The company’s core technology involves the insertion of an inert genetic construct, known as Nuclid™, into various food system products, including inputs, feed, seed, food, and additives. This innovative approach enables rapid identification, often within hours, regardless of packaging or potential co-mingling, thereby significantly mitigating the impact of product recalls. Index Biosystems' solutions work alongside existing systems and extend traceability from seed to waste, including post-digestion stages. Their technology allows for a range of applications, including recall scope reduction, operational insights, GMO identification, fraud detection, feed and seed security, intellectual property tracking, and food system certification. By empowering clients to trace the origin of products even when the chain of custody is disrupted, Index Biosystems is positioned to enhance transparency and accountability in the food industry.

Granville Biomedical is a health tech company, specializing in the design of anatomical models to enhance health care training, advance patient education, and innovate device demonstration. Through extensive research and development involving mechanical, simulation, and biological testing, Granville Biomedical has designed a novel, biocompatible Nasopharyngeal (NP) swab for nasal specimen collection.

Dynamhex operates an emission monitoring platform that provides detailed insights into energy consumption data for individuals, corporations, and government entities. The platform enables users to measure their emission footprints and develop effective reduction strategies aligned with science-based targets. By employing geospatial analytics and advanced visualization techniques, Dynamhex helps city governments and businesses make informed, environmentally responsible decisions. This functionality supports climate leaders in their efforts to combat climate change by facilitating timely and data-driven decision-making.

Cipher Skin is a patented form of biometric sensors that measure 3-dimensional movement while integrating numerous high-quality metrics like heart rate, respiratory rate, and quality and autonomic tone. These simultaneous set of metrics creates a 3D picture of how the body is moving, called the Digital Mirror.

Developer of a battery diagnostic technology designed to decrease capital and operation costs of lithium-ion battery manufacturing. The company offers test equipment and software analytics to expand the use of impedance spectroscopy, from battery management integrated circuits to high-power, multi-channel cyclers, enabling battery manufacturers to drive down the cost and improve the efficiency of formation, storage, and tests.

Path Therapeutics, Inc. develops a novel neurometabolic, phenotypic drug discovery platform that lifts the hood of the cell and identifies novel targets to jump-start stalled drug discovery programs. The company through its phenotypic-screening technology screen repurposed libraries for which the molecular target is well-characterized to enable reverse identification of druggable proteins. The platform enables drug discovery across CNS disorders, including epilepsy, autism, and aging. Path Therapeutics, Inc. was incorporated in 2013 and is based in Calgary, Canada.

Developer of an imaging and medical platform designed to revolutionize the effective and non-invasive vitreoretinal treatments of various eye diseases. The company's platform leverages advanced imaging technology, embedded machine learning and laser technology to diagnose, plan, and treat diseased areas within the eye such as age-related macular degeneration, diabetic retinopathy, branch retinal vein occlusion, and glaucoma, enabling patients to reduce disease progression and receive effective treatment options get a cure for retinal diseases.

Developer of algorithm-based analytics technology designed to be used for the diagnosis of retinal and brain vascular injury. The company's technology decreases the time required to capture images and identifies and quantifies critical information in the images, enabling physicians to conduct early diagnosis and follow-up treatment efficacy along with improved patient care and reduced clinical costs.

SiDx is a health services provider that focuses on modernizing blood group testing through an innovative diagnostic platform. The company has developed a medical device utilizing micro-sensors arranged on a silicon chip, which are activated by laser technology to detect reactivity to various compounds. This approach allows physicians to obtain test results during patient visits, significantly speeding up the care process and reducing costs associated with traditional testing methods. By enhancing the efficiency and accessibility of diagnostic services, SiDx aims to improve patient outcomes and streamline healthcare delivery.

ProbiusDx Inc. is a manufacturer of portable diagnostic devices that utilize an electronic sensing platform to analyze multiple target proteins in real time. This technology allows healthcare professionals to recommend suitable therapies for patients requiring critical care in clinical environments. Founded in 2015 and headquartered in El Cerrito, California, ProbiusDx is focused on enhancing diagnostic capabilities and improving patient outcomes through advanced, accessible diagnostic solutions.

Vivid Genomics specializes in developing non-invasive genomic tools aimed at identifying suitable candidates for clinical trials, particularly in the field of neurodegenerative diseases. By leveraging machine learning and genomic data, the company's innovative approach allows for the stratification and screening of patients, thereby assisting pharmaceutical companies in selecting the most appropriate participants for their clinical trials. This targeted patient selection enhances the likelihood of trial success, ultimately facilitating the approval process for new treatments.

FluoretiQ Limited is a medical device company based in Bristol, United Kingdom, that focuses on developing advanced technologies for the rapid identification of harmful bacteria. Founded in 2017, the company has created a diagnostic platform known as NANOPLEX, which utilizes proprietary nanomaterials and optical sensing technologies to detect bacterial pathogens in under 15 minutes. This innovative approach combines receptor-mediated sensing with quantum-enhanced optics, facilitating early diagnosis and enabling healthcare professionals to prescribe effective antibiotic treatments more efficiently. FluoretiQ's user-friendly products support accurate same-day diagnoses, ultimately improving patient outcomes by ensuring timely and appropriate antibiotic selection.

Altis Labs is a clinical information company located in Toronto, where it leverages expertise in artificial intelligence and medicine. The company focuses on developing AI-powered software designed to predict drug efficacy and accelerate clinical development. By utilizing deep learning-based imaging biomarkers and proprietary real-world imaging data combined with clinical context, Altis Labs enables biopharma companies to measure treatment effects more accurately and earlier in the clinical trial process. This innovative approach aims to enhance the speed and success rate of late-stage trials, ultimately guiding personalized treatment and facilitating therapeutic research and development.

PhenoTips is a computer software company that provides solution for clinical genetics, phenotyping, and human phenotype ontology. It offers smart software solutions streamlined for clinical use that can be integrated with existing electronic health records. The company was founded in 2014 and headquartered in Ontario, Canada.

Developer of a diagnostic tool designed for monitoring tissue perfusion and assessing muscle compartment pressure and bleeding in trauma patients. The company system stops patients from unnecessarily getting recommended for emergency fasciotomies, helping doctors save lives by providing real-time and trending blood flow monitoring of injured limbs.

Oxford Brain Diagnostics Ltd develops a Cortical Disarray Measurement (CDM) platform that uses magnetic resonance imaging (MRI) scans for clinical research and diagnosis to track the progress of dementia. The tool provides an index of the health of the cellular circuits in a patient's brain. The micro-structural assessment provides an analysis regarding the probability of developing dementia after studying the memory complaints. The company was incorporated in 2018 and is based in Oxford, United Kingdom.

QSM Diagnostics, Inc. is a Boston-based company founded in 2014 as a spin-out from the Goluch Group at Northeastern University. The company specializes in developing and manufacturing point-of-care diagnostics aimed at identifying bacterial infections, particularly ear infections caused by Pseudomonas aeruginosa in dogs. With decades of experience in the development and commercialization of medical devices, QSM Diagnostics focuses on electrochemical sensors and related medical devices to enhance diagnostic accuracy and speed. The company's expertise in sensor technology positions it to address critical needs in veterinary diagnostics.

Developer of stem cell therapy drugs intended to treat patients suffering from immune disorders. The company's therapies include drugs that are a less toxic alternative to current drugs which reduces morbidity and mortality from graft-vs-host-disease in bone marrow transplant, enabling patients to get treatment for blood cell disorders.

Caristo Diagnostics Limited, based in Oxford, United Kingdom, specializes in artificial intelligence-driven software for cardiovascular diagnostics. Founded in 2018, the company focuses on improving heart health assessments through its advanced imaging technology. By developing tools that analyze Cardiac Computed Tomography Angiography (CCTA), Caristo enables the measurement of Fat Attenuation Index (FAI) during routine heart check-ups. This innovative approach enhances the diagnostic accuracy of coronary angiograms, allowing healthcare professionals to identify inflammation in the coronary arteries and predict risks of heart attacks, strokes, and diabetes. Through its proprietary technology, Caristo Diagnostics aims to support medical professionals in making informed treatment decisions to better manage cardiovascular health.

Nostos Genomics UG, based in Berlin, Germany, specializes in developing an AI-driven variant interpretation platform aimed at improving the diagnosis of genetic diseases. The company's innovative platform partners with genetic testing laboratories to provide clear and efficient diagnoses for individuals affected by genetic disorders. By utilizing a unique blend of machine learning and synthetic biology, Nostos Genomics can characterize genetic mutations at scale and automate the interpretation process, enhancing the overall diagnostic capabilities of genetic testing labs.

ManagingLife is tackling the chronic pain and opioid crisis head-on. Chronic pain drives more health plan costs than any other chronic condition, and is the number one reason for disability claims. It is a costly problem that plan sponsors are increasingly looking for solutions from their health plans and disability carriers. Our industry-leading digital solution helps patients and doctors better measure, monitor, and manage chronic pain. As a result, we: * reduce absenteeism for employers * lower costs for health plans * shorten and prevent short and long-term disability claims Our solution is used by over 45,000 people worldwide and is licensed by Green Shield Canada and RBC Insurance, who collectively have more than 2.5 million lives under coverage. It is used at 7 hospitals, including a VA hospital in SF and Canada's largest academic hospital, University Health Network. ManagingLife was founded in 2012 and headquartered in Toronto, Ontario.

Arma Biosciences is a Toronto-based developer of a sensor platform designed for continuous monitoring of various physiological markers. The platform's sensing tips are compatible with multiple biological fluids, including saliva, blood, urine, sweat, and tears, allowing for rapid development to detect diverse health indicators. This technology enables users to access critical information regarding their health status, including the monitoring of cardiac biomarkers that are indicative of heart failure progression. By facilitating personalized health monitoring, Arma Biosciences aims to enhance individual awareness and management of health conditions.

Swiftsure Innovations provides registered nurses with the tools required to improve patient outcomes. It develops a medical device that enhances oral care for patients on life support with the aim of decreasing the incidence of ventilator-acquired pneumonia, length of mechanical ventilation, and length of hospital stay. Creative Destruction Labs supports the company.

Redesign Science Inc is a biotechnology company based in New York, established in 2017, that specializes in small molecule drug discovery. The company employs advanced techniques, including first-principles physics and artificial intelligence, to simulate protein targets at the atomic level. This approach allows Redesign Science to identify subtle drug opportunities that conventional computational models may overlook. By focusing on the development of first-in-class small molecules, the company aims to address emerging and challenging targets associated with significant unmet medical needs. Their innovative methodologies not only enhance the understanding of biological pathways and disease mechanisms but also drive the commercialization of new therapeutic solutions.

FluidAI Medical is focused on developing an innovative implantable biochip equipped with biosensors designed to detect post-operative complications, including internal bleeding, fluid leakage, and infections within the abdominal cavity. This advanced biosensor continuously collects data, identifying complications as they arise, and provides real-time notifications to both patients and healthcare providers. Specifically, the device aims to manage risks associated with surgeries by monitoring for anastomotic leakage, which involves gastrointestinal fluid leaking into the abdominal cavity. The biosensor is integrated into a catheter, where it resides within the abdominal cavity, while a monitoring unit remains external. When the biosensor detects changes indicative of a leak, it transmits alerts through the catheter to the external monitor. Data is continuously uploaded to the cloud for further analysis, ensuring timely alerts are sent to patients' smartphones, prompting them to seek medical attention, while offering detailed information to their doctors. Founded in 2014 and based in Kitchener, Canada, FluidAI Medical serves physicians, surgeons, hospitals, and patients with its groundbreaking technology.

Aifred Health Inc. develops and offers deep-learning based clinical decision tool for physicians to enable personalized medicine to psychiatry. The company's application software offers treatment prediction, interpretability, patient data tracking, and electronic patient record. Aifred Health Inc. was incorporated in 2017 and is headquartered in Montreal, Canada.

Nplex Biosciences is a biotechnology company based in the United States that specializes in proteomic technology. The company has developed a platform that utilizes DNA nanotechnology to understand, detect, and treat diseases. Nplex offers a range of instruments and automation tools for measuring multiple proteins from blood samples, providing cost-effective solutions for protein data analysis. Its technology integrates seamlessly with industry-standard cytometers, enabling high-throughput analysis and the development of custom protein panels. Nplex aims to enhance existing instruments and workflows while facilitating automation in proteomic research and applications.

HumanSignal, formerly known as Heartex, Inc, develops a comprehensive platform focused on data labeling and annotation to assist businesses in creating artificial intelligence products. The platform enables companies to efficiently manage and annotate training data, significantly reducing the time spent on preparing datasets for machine learning. Its features include support for unlimited projects, integration with various models, and a robust API, which collectively enhance collaboration, quality assurance, and analytics in the data labeling process. By streamlining these tasks, HumanSignal empowers organizations to generate accurate and competitive AI models at scale, all while facilitating a more efficient workflow for teams involved in data management and analysis. The company is headquartered in San Francisco, California.

Motryx provide quality assurance insights throughout the transport of blood samples.

Coastal Genomics Inc. engages in research and development for the life sciences automation sector. The company offers ranger technology, than enables the complete automation of gel based size selection of biomolecules. The company was incorporated in 2012 and is based in Burnaby, Canada.

Developer of minimally invasive intervention technologies intended to provide a diagnosis of cardiovascular disease. The company's platform leverages a team of scientists, clinicians, and engineers to design tools that improve image-guided procedures for cardiovascular diseases, enabling doctors to perform these interventions with greater precision and potentially reducing risks and complications for patients.

Zilia is a medical technology company that has developed a non-invasive platform utilizing imaging, spectrometry, and artificial intelligence to assess various biomarkers in the human eye. The focus is primarily on measuring oxygen levels, which play a vital role in ocular diseases such as glaucoma, diabetic retinopathy, and age-related macular degeneration. Zilia's flagship product, the Zilia Ocular, is an innovative ocular oximeter that integrates hardware and software to assist eye care professionals in the prevention, diagnosis, and management of these conditions. The technology combines interactive analytical software with devices and data management tools to provide valuable insights into the metabolic state of ocular tissues and their relationship to overall health, enabling healthcare providers and researchers to effectively monitor and understand eye diseases.

Operator of a SaaS (software-as-a-service) medical device company that uses artificial intelligence (AI) technologies to detect the early stages of diseases such as cancer. The company's tools are based on machine learning and deep learning and act as modules to analyze multiple imaging techniques including endoscopy, ultrasound, MR, and CT (computed tomography) imaging, it provides clinicians with better accuracy in diagnosis through real-time image analysis and generates an instant patient report at the end of an endoscopy procedure (Health Canada approved), it is partnered with manufacturers and distributors of medical devices and started processes for commercializationmore

Biotx.ai is a company focused on advancing precision medicine through the development of innovative biomarkers. Its drug discovery platform utilizes artificial neural networks to analyze significant patterns, facilitating the identification of potential diagnostics and therapeutics. By monitoring individual patient responses, the platform helps stratify participants in clinical studies, enabling healthcare providers to address unmet medical needs more effectively. Through its technology, Biotx.ai aims to enhance decision-making in medical practice and improve patient outcomes.

Developer of regenerative therapies technology designed to help in tissue regeneration. The company's therapies use a purinergic system that regulates and maintains tissue homeostasis and restores adenosine levels, enabling users to harness the healing potential of adenosine for tissue regeneration.

LifeBooster is a predictive analytics company focused on health and safety, utilizing wearable technology to help self-insured industrial workforces reduce preventable workplace injuries. Their primary offering, ErgoSenz, consists of wireless motion capture sensors and a cloud-based risk analytics engine. This system enables health and safety professionals to identify and assess risk factors associated with musculoskeletal disorders (MSDs), which account for a significant percentage of workplace injuries and result in substantial financial costs to businesses. ErgoSenz provides an objective evaluation of workforce biomechanics, allowing companies to tailor training and risk mitigation strategies to specific needs. In addition to proactive injury prevention, the system facilitates comprehensive incident analysis, enabling safety professionals to reconstruct events surrounding injuries. By shifting the focus from reactive to proactive health and safety measures, LifeBooster aims to eliminate preventable injuries in the workplace.

Sonic Incytes Medical Corp is a medical device company based in Vancouver, Canada, focused on developing handheld ultrasound solutions for the assessment and monitoring of chronic liver diseases. Incorporated in 2012, the company aims to enhance routine liver health evaluation through non-invasive methods that provide reliable diagnostic accuracy. Its portable ultrasound devices are designed for point-of-care diagnostics and procedure guidance, enabling healthcare practitioners to improve the standard of care in quantifying conditions such as fatty liver disease. Through its innovative technology, Sonic Incytes seeks to facilitate better management of liver health for patients.

The company specializes in designing innovative wearable technology aimed at enhancing personal health and well-being. Its flagship product is a low-cost, secure eyeglass-based monitor that utilizes optical sensing to track both physical and mental health metrics. By employing blockchain technology, the company ensures the encryption of personal data, providing users with a secure means to access their health information. The device offers real-time feedback, particularly beneficial for individuals in high-stress professions such as nursing, law, and technology, as well as students and athletes. Additionally, the wearable pod helps users optimize their work sessions by estimating mental states, thus enabling better planning and deeper insights into cognitive performance throughout the day.

Developer of a health technology company delivering precision datasets from the gastrointestinal tract leveraging a capsule sampling technology and creating a paradigm shift in how GI health is diagnosed and treated. The company's product enables passive sampling of small bowel luminal fluid to leverage intestinal data to provide insights, enabling healthcare providers with direct sampling and analysis of targeted regions of the gastrointestinal tract.

16 Bit Inc. is a Toronto-based company that specializes in developing artificial intelligence software as a medical device, focusing on medical image analysis systems. The company is actively creating algorithms aimed at enhancing the diagnostic capabilities of physicians. Its notable projects include a breast cancer screening triaging algorithm, as well as systems for neurological emergency detection and pediatric bone age assessment. By improving the efficiency of interpreting medical images, 16 Bit Inc. aims to enhance the quality and accessibility of healthcare for all patients.

Prime Discoveries LLC specializes in microbiome testing, discovery, and research services, utilizing a technology platform that combines automation, machine learning, and computational biology. Founded in 2017 and headquartered in New York, the company serves both the healthcare and agricultural sectors. Prime Discoveries is focused on developing diagnostics technology for emerging pathogen infections, creating cost-effective and scalable assays that can be easily automated. Their rapid testing solutions aim to elucidate the intricate relationships between microbes and health, facilitating advancements in practical microbiome applications for researchers and professionals in various fields.

Leap Biosystems is a healthcare company focused on advancing medical technologies and astronaut medical training platforms to support future human space exploration initiatives. The organization is comprised of a team of Canadian professionals with expertise in medical, aerospace, research, and engineering fields. Leap Biosystems aims to provide innovative solutions that combine clinical medicine with technology, enabling effective medical care in remote environments. Their offerings include remote medical procedure guidance technology, designed to enhance the delivery of healthcare in challenging settings, ultimately changing lives and improving healthcare systems.

Sensor Medical improves surgical safety through force-sensing technology.

Obatala Sciences, a fat-on-a-chip biotechnology company, was incorporated to reduce the $2 Trillion economic burden associated with Obesity and Diabetes. Obatala is revolutionizing our view of body fat by highlighting its importance as a functional organ, and a regulator of body health and disease.

Nanology Labs Inc., founded in 2018 and based in Toronto, Canada, focuses on developing a nano-theranostic platform technology aimed at detecting and treating cancers. The company's flagship product, Manganescan, serves as a novel theranostic agent that functions both as an MRI contrast agent and a radio-sensitizer. Manganescan enhances the detection of brain tumors at early stages by producing Mn2+ ions, which oxygenate the tumor environment and improve the efficacy of radiation therapy. This innovative agent is three times more sensitive than existing Gadolinium-based contrast agents and is capable of crossing the blood-brain barrier, allowing for early and precise identification and targeting of brain cancer.

Prescryptive Health, Inc. is a digital health company based in Redmond, Washington, that operates a prescription benefits platform aimed at enhancing accessibility, affordability, and personalization in the medication market. Established in 2017, the company provides a range of services, including the analysis of existing plan designs, recommendations for new plans, and assistance with member enrollment. Its platform offers users, including employers, health plans, providers, pharmacies, and pharmaceutical companies, direct access to unbiased market pricing and essential information about prescribed treatments. This enables patients to understand their out-of-pocket expenses, insurance coverage, and available lower-cost alternatives at the point of care, thereby promoting informed decision-making in the prescription drug market.

Developer of a portable neuroimaging system designed to track and predict recovery of movement function during the rehabilitation of hemiparesis. The company's systems utilize a proprietary optical imaging system, assessment software, and data analytics to measure neural biomarkers and aid neurological rehabilitation, enabling therapists to make sustainable treatment decisions.

Panakeia makes cancer diagnosis simpler, faster and cheaper by eliminating the need for multiple tests.

SaluTech develops a conductive biomaterial (CBM) to treat the underlying cause of the arrhythmia. This CBM has the ability to reduce/diminish arrhythmia while being nontoxic, biocompatible, and inexpensive to produce.

Kheiron Medical Technologies Limited develops Mia, a mammography intelligent assessment tool that helps radiologists to detect breast cancer. Kheiron Medical Technologies Limited was formerly known as Maesterai Limited and changed its name to Kheiron Medical Technologies Limited in June 2016. The company was incorporated in 2016 and is based in London, United Kingdom with an additional location in San Francisco, California.

Synex Medical specializes in non-invasive blood testing technology, focusing on the development of a portable device that enables users to monitor metabolite concentrations without penetrating the skin. Utilizing a miniaturized magnetic resonance system, the company can accurately detect critical blood metabolites such as glucose, lactate, and ketones. This innovative approach employs only magnets and radio waves, ensuring there are no adverse health effects associated with its use. By providing precise information about metabolic health, Synex Medical aims to empower individuals to take proactive steps in managing their health and well-being.

Readout is a digital health company with a mission to help patients better manage their own health by providing novel, clinically-backed tools to easily measure health biomarkers. Biosense was launched in early 2020 as a Class 1 medical device in the clinical, consumer, and research market after a successful clinical trial. As the only clinically-backed breath ketone measurement handheld device+app, Biosense provides full-day feedback of ketosis with unlimited measurements leading to protocol adherence and better outcomes. Biosense is used by obesity and diabetes clinics for in-home testing of ketosis, pharma and academic trials, as well as DTC via https://mybiosense.com.

Developer of an artificial intelligence-powered consultation software designed to ensure patients receive care from cancer treatment centers. The company's software uses machine learning algorithms to provide the clinical team with AI-derived decision-making metrics utilizing data from thousands of patients, enabling clients to gain consultation and insights on the quality of cancer care before patients begin their treatment course and hospitals to increase clinical efficiency and improve quality of delivery of cancer care.

Ravata Solutions, founded in 2016 and based in Davis, California, specializes in developing medical devices for gene delivery, focusing on the creation of custom animal models. The company is dedicated to enhancing the production of transgenic models, which are crucial for pre-clinical research studies aimed at improving human disease modeling. By optimizing embryo viability and streamlining the process of creating transgenic organisms, Ravata enables researchers to conduct their studies more efficiently. This innovation has significant implications for advancing drug efficacy and medical genetics research, ultimately contributing to the development of better therapies and understanding of human diseases.

GenXys Health Care Systems Inc. specializes in precision prescribing software and pharmacogenetic solutions aimed at enhancing patient safety and medication efficacy while reducing healthcare costs. Based in Kelowna, Canada, the company’s innovative software analyzes interactions among medications, genetic factors, and health information to prevent adverse drug reactions. These reactions are a significant cause of morbidity, ranking as the fourth largest contributor to mortality in the United States, and many patients do not respond effectively to standard treatments. By addressing these critical issues, GenXys aims to promote personalized medicine, envisioning a future where its technology supports every prescription worldwide.

Mediphage Bioceuticals is a biotechnology company specializing in non-viral gene delivery solutions for gene therapy, cell engineering, and gene editing. The company’s flagship technology, ministring DNA (msDNA), is designed to be a safe and effective transgene delivery vector that addresses the limitations of traditional viral gene therapies. msDNA offers a versatile platform that can be produced at a significantly lower cost compared to existing options, making it an attractive alternative for researchers. By focusing on innovative solutions for genetic and infectious diseases that have limited or no treatment options, Mediphage Bioceuticals aims to enhance the effectiveness of gene delivery while ensuring patient safety.

Blue Mesa Health Inc., digital therapeutics company, develops and operates a platform to deliver diabetes prevention program. The company offers Transform, which is a digital health platform that helps in reversing prediabetes through health coaching and support. It product caters to healthcare sector. The company was founded in 2015 and is based in New York, New York. As of January 9, 2020, Blue Mesa Health Inc. operates as a subsidiary of Virgin Pulse, Inc.

HealthChain is a developer of software solutions aimed at enhancing efficiency within healthcare management systems by replacing outdated technologies and paper-based processes. The company's offerings utilize advanced technologies, including blockchain, to facilitate a secure and streamlined flow of medication information. By embedding automated prescribing rules into its platform, HealthChain ensures precision in drug therapy and optimizes patient outcomes. The software is designed to improve the privacy and security of prescriptions without disrupting existing workflows, thereby enabling healthcare professionals to deliver the appropriate medication to the right patient under the right circumstances.

Cosm Medical is a VC-backed health-tech startup building and commercializing a software-enabled medical device platform to improve the lives of women affected by pelvic floor disorders.

Aluna is the San Francisco based tech company that’s disrupting respiratory illnesses through machine learning. We’re creating the standard of care for lung health, and envision being the global leader in the respiratory space. Aluna was founded with a mission - to track, and ultimately have control over chronic diseases. To achieve it, we’ve turned an expensive hospital device that required clinician supervision into a self-management system that helps keep you healthy.

ProT Therapeutics

Systolik Digital Health is a medical device manufacturer providing solutions for cardiologists.

Orpyx Medical Technologies Inc. specializes in the development of mobility sensor devices aimed at diabetic patients. The company's flagship product, the Orpyx SI sensory insoles, utilizes advanced sensor technology to monitor pressure, temperature, and movement, thereby aiding in the management and prevention of diabetic foot ulcers and limb loss. In addition to the insoles, Orpyx offers Kinetyx, a mobile in-shoe pressure management system that collects clinical plantar pressure data for applications in sports medicine, therapeutic interventions, and footwear design. Another product, SurroGait Rx, is designed to enhance mobility and balance for multiple sclerosis patients suffering from loss of protective sensation in their feet. Founded in 2010 and headquartered in Calgary, Canada, Orpyx Medical Technologies is committed to empowering individuals with diabetes to maintain their mobility while promoting a prevention-focused healthcare approach.

Instantia Labs

Awake Labs is building an AI-powered app accompanied by a wearable to collect real-time data to empower care for neurological disorders, starting with autism. Reveal Stories, the application, allows users to track behavior by voice, text, or file to facilitate collaboration within the care team. Reveal Band, the wearable, tracks physiological indicators of anxiety to give real-time insights and predict states of high-anxiety. Our platform is being designed to collect data from any available wearable on the market to make our technology more accessible.

Oncoustics focuses on enhancing clinical workflow productivity and increasing the accessibility and affordability of ultrasound technology for diagnostic imaging. The company has developed advanced artificial intelligence solutions that analyze raw ultrasound signals to identify differences between healthy and diseased tissues, thereby revealing novel acoustic biomarkers. This innovation allows medical professionals to categorize tissues effectively, serving as a virtual biopsy system and addressing significant unmet clinical needs in disease treatment monitoring. By making ultrasound technology available to non-experts, Oncoustics aims to improve diagnostic capabilities in various healthcare settings.

Phenomic AI is a developer of a drug discovery platform designed to discovery and optimize therapeutics directly against phenotypic assays.The company's platform uses artificial intelligence to analyze phenotypes in complex disease models including high-content co-culture and 3D assays, enabling pharmaceutical companies to discover drugs in an easier way.

HealthChain is a developer of software solutions aimed at enhancing efficiency within healthcare management systems by replacing outdated technologies and paper-based processes. The company's offerings utilize advanced technologies, including blockchain, to facilitate a secure and streamlined flow of medication information. By embedding automated prescribing rules into its platform, HealthChain ensures precision in drug therapy and optimizes patient outcomes. The software is designed to improve the privacy and security of prescriptions without disrupting existing workflows, thereby enabling healthcare professionals to deliver the appropriate medication to the right patient under the right circumstances.

Denti.AI is a cloud-based service that utilizes machine learning to analyze dental images, aiding dentists in identifying pathologies while reducing false positives. The platform enhances patient care by offering objective assessments and facilitating earlier treatments. Its capabilities include generating electronic medical records, creating dental charts, and providing analytics for dental chains and insurers. Additionally, Denti.AI automates the charting of dental conditions and past treatments through voice dictation, which streamlines clinical workflows and increases productivity for dental practices. The system is designed to seamlessly integrate with various practice management and imaging equipment, ultimately improving the efficiency and revenue of dental organizations.

Correlia Biosystems, Inc. develops microarray technology that integrates platforms for research and diagnostic applications. It offers protein detection service by analyzing micro-samples of blood. The company's technology provides multiplexing for large protein panels, which includes cytokines and post-translational modifications with unparalleled speed and automation, enables healthcare providers to quantify proteins for proteomic and pharmaceutical applications, and also allows doctors to make immediate and informed treatment decisions. Correlia Biosystems, Inc. was founded in 2013 and is based in Berkeley, California.

SomaDetect Inc. is an agricultural technology company based in Fredericton, Canada, that focuses on providing dairy farmers with real-time analytics of milk components. Founded in 2016, the company has developed advanced sensor technology capable of measuring critical indicators such as fat content and somatic cell counts in milk. This innovative system enables farmers to conduct automated analysis without the need for chemicals or consumables, allowing them to identify issues early, manage herd health, and optimize milk quality. By delivering detailed insights during every milking, SomaDetect supports farmers in making informed decisions that enhance production while reducing unnecessary antibiotic use and ensuring high-quality milk enters the bulk supply.

See-Through Scientific